Emerging research suggest this peptide, a dual activator targeting both the gut-brain axis and GIP , appears to provide a significant step forward for body management . Preliminary human trials have indicated impressive decreases in visceral tissue, possibly outperforming other obesity medications . Nevertheless , additional study is necessary to f